GlobeNewswire Inc.··Researchandmarkets.ComCTLA-4 Inhibitor Pipeline Expands With 50+ Candidates in Development Across 40+ Companies
Over 40 companies develop 50+ CTLA-4 inhibitor candidates for cancer immunotherapy. Recent FDA approvals and focus on combination strategies drive pipeline expansion.
BMYCELGrAZNIVBIYAGEN+1FDA approvalclinical trials